

mammal which comprises administering to said mammal an effective amount of a monoclonal autoantibody selected from the group consisting of SCH 79.08, 01, 04, A2B5, HNK-1, antigen binding fragments thereof, monoclonal autoantibody capable of inducing remyelination of central nervous system axons and synthetic autoantibody capable of inducing remyelination of central nervous system axons.

---

- F 2 ✓
9. (Amended) A method of treating a demyelinating disease of the central nervous system in a mammal in need of such therapy which comprises administering to said mammal an effective amount of a monoclonal autoantibody selected from the group consisting of SCH 79.08, 01, 04, A2B5 and HNK-1, antigen binding fragments thereof, monoclonal autoantibody capable of inducing remyelination of central nervous system axons and synthetic autoantibody capable of inducing remyelination of central nervous system axons.
- 

- Sub G1  
F 3
19. (Amended) A pharmaceutical composition comprising as the active agent, a monoclonal autoantibody selected from the group consisting of an antigen binding fragment of SCH 79.08, monoclonal autoantibody capable of inducing remyelination of central nervous system axons and synthetic autoantibody capable of inducing remyelination of central nervous system axons.
- 

20. (Amended) A method of stimulating remyelination of central nervous system axons in a mammal which comprises administering to said mammal an effective amount of a